Gyre Therapeutics, Inc.
GYRE
$6.68
$0.142.14%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 19.14% | -34.32% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 19.14% | -34.32% | |||
| Cost of Revenue | 80.03% | -29.60% | |||
| Gross Profit | 15.92% | -34.55% | |||
| SG&A Expenses | -11.07% | -20.33% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 16.06% | -0.15% | |||
| Operating Income | -10.10% | -10,591.67% | |||
| Income Before Tax | 19.94% | -27,218.18% | |||
| Income Tax Expenses | -129.87% | -57.77% | |||
| Earnings from Continuing Operations | 23.19% | -1,260.10% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -55.74% | 2,419.33% | |||
| Net Income | -2.97% | -497.74% | |||
| EBIT | -10.10% | -10,591.67% | |||
| EBITDA | -3.86% | -1,562.33% | |||
| EPS Basic | 19.46% | -661.38% | |||
| Normalized Basic EPS | -555.45% | 212.24% | |||
| EPS Diluted | 16.61% | -560.09% | |||
| Normalized Diluted EPS | -555.45% | 212.24% | |||
| Average Basic Shares Outstanding | 10.14% | 0.23% | |||
| Average Diluted Shares Outstanding | 10.14% | 0.23% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||